Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells
(MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM, grade
IV astrocytoma) and a potential mechanism of treatment resistance to chemoradiotherapy.
Tadalafil, an FDA-approved drug with inexpensive cost and excellent safety profile, has been
shown to effectively reduce MDSCs and restore T-cell activation in the peripheral blood and
in the tumor microenvironment. The purpose of this study is to investigate the impact of
targeting MDSCs in newly diagnosed IDH-wildtype grade III-IV astrocytoma by combining
tadalafil with standard of care radiation therapy (RT) and temozolomide (TMZ).